Cyclacel Pharmaceuticals, Inc.
(NASDAQ : CYCC)

( )
CYCC After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. 0.72%52.850.9%$1374.69m
JNJJohnson & Johnson 1.40%179.460.7%$1371.52m
BMYBristol-Myers Squibb Co. 0.63%76.671.0%$1204.82m
MRKMerck & Co., Inc. 0.45%93.980.7%$1144.89m
ABBVAbbVie, Inc. -1.98%148.021.9%$1115.58m
LLYEli Lilly & Co. 1.25%302.571.1%$903.32m
AZNAstraZeneca Plc 0.30%66.411.0%$519.21m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 0.66%142.970.0%$461.53m
VERUVeru, Inc. 5.53%14.120.0%$336.28m
NVSNovartis AG 1.45%90.720.2%$254.85m
GSKGlaxoSmithKline Plc 0.53%44.760.2%$244.47m
HZNPHorizon Therapeutics Plc -3.29%87.385.4%$193.81m
NVONovo Nordisk A/S 0.07%107.830.1%$190.87m
SGENSeagen Inc. -0.22%139.345.7%$181.36m
VTRSViatris, Inc. -1.44%11.630.0%$163.74m

Company Profile

Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.